Carnival of Biotechnology
Lots of interesting developments since the last edition: Pfizer’s high-profile drug failiure, a new law against violent extremists, good news for Merck, and good and bad news for the biotechnology industry as a whole. News and Trends The Washington Times has an update on the signing of the Animal Enterprise Terrorism Act. Bolstered by recent […]